Sermorelin · Research brief

CJC 1295 vs Sermorelin: Secretagogue Comparison

Real Peptides Research TeamEditorial

Updated March 3, 202610 min read

60 WORDS

Short answer

Sermorelin and CJC-1295 bind the same receptor. Same target, same downstream pathway, same dependence on pituitary somatotrophs to do the actual work. So the entire practical difference in the CJC 1295 vs Sermorelin comparison comes down to one variable: how long each molecule survives in plasma before dipeptidyl peptidase-4 (DPP-4), the enzyme that clips peptides near the N-terminus, takes it…

Key takeaways

Sermorelin and CJC-1295 share the GHRH receptor and the GRF 1-29 backbone, so the CJC 1295 vs Sermorelin difference is plasma stability, not receptor affinity or a different mechanism.
CJC-1295 without DAC is the only fair head-to-head comparator for Sermorelin; the DAC version converts pulsatile release into multi-day sustained exposure and answers a different question.
Sermorelin acetate and Sermorelin are the same 29-amino-acid peptide, differing only by acetate counterion, and net peptide content on the certificate of analysis is always lower than the vial's gross weight.
GHRP-2, GHRP-6, Hexarelin and MK-677 act on GHSR-1a, a completely separate receptor from the one Sermorelin binds, which is why combined GHRH and ghrelin mimetic designs appear throughout the literature.
IGF-1 LR3 acts at the IGF-1 receptor downstream of the pituitary and suppresses endogenous GH, making it a feedback comparator rather than a secretagogue alternative.
Real Peptides supplies these compounds for laboratory research only, with small-batch synthesis and publicly verifiable certificates of analysis.

Our team supplies research-grade GHRH analogs and ghrelin receptor agonists to laboratories, and this is the question research groups ask us most often before designing a growth hormone axis study. Most of the confusion doesn't come from these two compounds. It comes from stacking them against molecules that don't share a receptor with either one.

CJC 1295 vs Sermorelin: what is the actual difference?

In the CJC 1295 vs Sermorelin comparison, both compounds are growth hormone releasing hormone (GHRH) receptor agonists built on the same 29-amino-acid sequence. Sermorelin is native GRF 1-29 with a plasma half-life measured in minutes. CJC-1295 carries amino acid substitutions that resist DPP-4 cleavage, and the DAC version binds serum albumin for multi-day exposure.

The misconception worth correcting straight away is that a longer half-life means a stronger signal. It doesn't. A GHRH analog can only push somatotrophs as hard as hypothalamic somatostatin tone permits, so extending exposure reshapes the release curve rather than lifting its ceiling. What follows covers receptor class across the major secretagogues, how the DAC modification changes study design, what the acetate salt form on a vial label actually means, and where IGF-1 LR3 and recombinant hGH sit outside the secretagogue category entirely.

Two receptors do all the work in this category

Every compound people compare against Sermorelin acts through one of two receptors, and knowing which one collapses most of the confusion. The GHRH receptor group includes Sermorelin (GRF 1-29), CJC-1295 without DAC (also written as modified GRF 1-29), CJC-1295 with DAC, and Tesamorelin. These bind the pituitary GHRH receptor and trigger a release pulse that stays under somatostatin control.

The second group binds GHSR-1a, the growth hormone secretagogue receptor that native ghrelin acts on. GHRP-2, GHRP-6, Hexarelin, Ipamorelin and the orally active non-peptide MK-677 all sit here. Ghrelin mimetics amplify pulse amplitude and, by literature accounts, blunt somatostatin tone rather than simply mimicking GHRH.

That's why hexarelin vs sermorelin and ghrp-2 vs sermorelin aren't like-for-like comparisons. They're different receptors on the same cell, which is precisely why the published literature so often examines a GHRH analog and a GHRP together and reports a larger combined response than either produces alone. The mk 677 vs sermorelin question is the same structural mismatch with an added wrinkle: MK-677 is oral and non-peptide, so it isn't even the same chemical class.

Our team has seen more study designs derailed by this one category error than by anything to do with compound quality.

Half-life, the DAC modification, and what the vial label leaves out

Sermorelin's plasma half-life is reported in the range of roughly 10 to 20 minutes, which is close to native GHRH behaviour and produces a sharp, self-limiting pulse. CJC-1295 without DAC substitutes four amino acids to resist DPP-4 degradation and is commonly reported at around 30 minutes. Same pulse shape, slightly wider window.

CJC-1295 with DAC is a different exposure model. The drug affinity complex forms a covalent bond with serum albumin, and published pharmacokinetic work in healthy adults has reported a terminal half-life of several days. That converts discrete pulses into a sustained elevation of GH and IGF-1, which is useful in some models and actively destroys the pulsatility signal in others. So in a sermorelin vs cjc 1295 design, the no-DAC version is the honest comparator and the DAC version is a separate question.

Here's the detail most comparisons skip entirely. The sermorelin acetate vs sermorelin question isn't a comparison of two compounds. Sermorelin acetate is the acetate salt of the same peptide, with the counterion left behind from HPLC purification. Net peptide content is always lower than the gross weight printed on the vial, because that weight includes counterion and residual water. The certificate of analysis is the only place that net figure appears, and ignoring it means every mg per mL calculation in the study is quietly wrong. Verify the CAS number and the net peptide content before two vials are ever treated as equivalent.

Where the comparison stops being a secretagogue question

Two of the most-searched comparisons involve compounds that aren't secretagogues at all. IGF-1 LR3 is an 83-amino-acid analog of insulin-like growth factor 1 with an arginine substitution at position three and a 13-residue N-terminal extension, modifications that sharply reduce binding to IGF binding proteins and extend circulating time. It acts on the IGF-1 receptor, downstream of the pituitary, and exerts negative feedback on endogenous GH output. In any sermorelin vs igf-1 lr3 design, the two compounds are on opposite ends of the same axis. One asks the pituitary to release; the other delivers the end product and tells the pituitary to stop.

Recombinant human growth hormone is the other outlier. Somatropin is the full 191-amino-acid protein acting directly at the GH receptor, producing non-pulsatile, supraphysiologic exposure that suppresses endogenous GHRH signalling. The sermorelin vs exogenous rhgh framing that circulates on research forums is really a question about whether a study wants to measure axis function or bypass it.

Every compound named here is supplied for laboratory research only and is not a drug product intended for human or veterinary use. Our team's position on procurement is simple: purity percentage, mass spectrometry confirmation and a publicly verifiable certificate matter more than the compound you picked, because an unverified vial makes a clean comparison impossible.

CJC 1295 vs Sermorelin and the Wider Secretagogue Field: Receptor, Half-Life and Class Comparison

This table maps every compound commonly benchmarked against Sermorelin by receptor target, reported half-life and the property the literature emphasises. Half-life values are reported ranges from the published literature, not study parameters or guidance.

Compound	Receptor target and class	Reported plasma half-life	What the literature emphasises	Bottom line for study design
Sermorelin (GRF 1-29)	GHRH receptor; 29-amino-acid N-terminal fragment of human GHRH	Short, roughly 10 to 20 minutes	Sharp pulsatile release that remains under somatostatin feedback control	The closest available analog to native GHRH signalling when pulse architecture is the measured variable
CJC-1295 without DAC	GHRH receptor; four substitutions resist DPP-4 cleavage	Short, commonly reported around 30 minutes	Same pulse shape as Sermorelin with modestly extended plasma stability	The only true like-for-like comparator to Sermorelin, since receptor and sequence backbone are shared
CJC-1295 with DAC	GHRH receptor plus drug affinity complex binding serum albumin	Long, reported in days rather than minutes	Sustained GH and IGF-1 elevation instead of discrete pulses	A different exposure model, not a drop-in substitution for Sermorelin in pulsatility work
GHRP-2	GHSR-1a ghrelin receptor; synthetic pentapeptide	Short, reported well under an hour	Robust GH release with reported modest rises in cortisol and prolactin	Separate receptor from Sermorelin, which is why combined GHRH and GHRP designs appear so often
GHRP-6	GHSR-1a; hexapeptide	Short	Pronounced central appetite signalling through ghrelin pathways	Feeding confound makes it a weak isolated comparator in metabolic models
Hexarelin	GHSR-1a plus reported CD36 binding in cardiac tissue	Short	Most potent acute GH releaser of the GHRP series, with rapid desensitisation described under continued exposure	Tachyphylaxis limits long-run models; Sermorelin shows neither the same acute spike nor the same fall-off
MK-677 (ibutamoren)	GHSR-1a; orally active non-peptide	Long relative to the peptide GHRPs, reported in hours	Sustained 24-hour GH and IGF-1 elevation, with reported increases in appetite and fasting glucose	Oral availability suits longer rodent models but introduces metabolic confounds Sermorelin does not
IGF-1 LR3	IGF-1 receptor; 83-amino-acid analog with reduced IGFBP affinity	Substantially longer than native IGF-1	Acts downstream of the pituitary and suppresses endogenous GH through negative feedback	Not a secretagogue; it bypasses the axis Sermorelin is used to probe
Recombinant hGH (somatropin)	GH receptor directly; full 191-amino-acid protein	Hours following subcutaneous delivery in reported studies	Non-pulsatile supraphysiologic exposure that suppresses endogenous GHRH signalling	The exposure reference standard, but it removes the feedback biology secretagogue research exists to measure

What If: Secretagogue Comparison Scenarios

What if Sermorelin degrades too fast for the assay window?

Move the comparator to CJC-1295 without DAC before reaching for a DAC-modified analog. The four amino acid substitutions block DPP-4 cleavage and extend reported half-life to roughly 30 minutes while preserving the same receptor interaction and pulse morphology. That keeps the GHRH signalling variable intact and changes only stability. Switching straight to CJC-1295 with DAC alters the exposure profile from pulses to a multi-day plateau, which means the study is no longer measuring the same phenomenon.

What if GH response is strong at week one and flat by week four?

Check whether the compound in use is a ghrelin receptor agonist rather than a GHRH analog. Hexarelin in particular is described in the literature as producing the largest acute GH release of the GHRP series alongside rapid desensitisation under continued exposure, a pattern GHRH analogs don't reproduce in the same way. Receptor downregulation at GHSR-1a is the usual explanation. If durability over weeks is the endpoint, the receptor class is the design flaw, not the compound quality.

What if the real question is Sermorelin against recombinant hGH?

Decide first whether the study needs an intact feedback loop. Sermorelin works upstream, so GH output remains subject to somatostatin braking and pituitary reserve, meaning the response is capped by the animal's own axis. Recombinant hGH bypasses that entirely, delivering the 191-amino-acid protein at the GH receptor and suppressing endogenous GHRH signalling in the process. Forum threads posing sermorelin vs exogenous rhgh as a ranking question are usually asking about potency when the actual difference is physiological regulation.

What if two vials of the same compound produce different results?

Pull both certificates of analysis and compare purity percentage, mass spectrometry identity confirmation and net peptide content before suspecting anything about the model. Acetate salt forms carry variable counterion and residual water fractions, so two vials labelled with identical gross weights can differ in actual peptide mass. Our team has traced more than a few inconsistent runs to that gap. Verifying CAS number and molecular identity at procurement eliminates the variable permanently.

The Unglamorous Truth About Ranking Growth Hormone Secretagogues

Here's the honest answer: there is no winner in the cjc 1295 vs sermorelin debate, because the two compounds are doing the same thing on a different clock. Ranking them by potency is a category error. The genuinely consequential decisions are which receptor a study targets, whether the design needs pulsatile or sustained exposure, and whether the material in the vial is what the label claims. Compound selection is maybe the third most important factor in a clean GH axis experiment. Material verification is the first.

Our catalog reflects how these compounds group in practice. GHRH comparisons typically run from Sermorelin and CJC-1295 no DAC, while ghrelin receptor work draws on GHRP-2, Hexarelin and MK-677. Downstream signalling studies use IGF-1 LR3. The full growth hormone secretagogue collection and our published certificates of analysis are the two pages worth reading before procurement.

The cjc 1295 vs sermorelin question keeps getting framed as a contest because comparison content rewards winners, and biology doesn't. What actually separates a useful GH axis study from a noisy one is whether the researcher knew which receptor they were hitting, whether the exposure profile matched the endpoint, and whether the peptide in the vial was verified before the first data point was recorded. Get those three right and the compound choice mostly takes care of itself.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Both are GHRH receptor agonists built on the same 29-amino-acid GRF 1-29 sequence, so the difference is plasma stability rather than mechanism. Sermorelin has a reported half-life of roughly 10 to 20 minutes, while CJC-1295 without DAC carries four amino acid substitutions that resist DPP-4 cleavage and extend that window to around 30 minutes. CJC-1295 with DAC binds serum albumin and is reported to persist for days, which changes the exposure model from pulses to a plateau.

CJC-1295 without DAC is the like-for-like comparator. It shares the receptor, the sequence backbone and the pulsatile release profile with Sermorelin, so stability is the only variable that changes. CJC-1295 with DAC produces multi-day sustained GH and IGF-1 elevation instead of discrete pulses, which makes it a different experimental question rather than a substitution.

Yes. Sermorelin acetate is the acetate salt of the same 29-amino-acid peptide, with the counterion left over from HPLC purification. The practical consequence is that net peptide content is lower than the gross weight printed on the vial, because that weight includes counterion and residual water. The certificate of analysis is the only place the net figure is stated.

MK-677, also called ibutamoren, is an orally active non-peptide agonist at GHSR-1a, the ghrelin receptor, while Sermorelin is an injectable peptide acting at the GHRH receptor. They are different chemical classes acting on different receptors. The literature describes MK-677 producing sustained 24-hour GH and IGF-1 elevation along with reported increases in appetite and fasting glucose, confounds that Sermorelin does not introduce.

Hexarelin is described in the published literature as the most potent acute GH releaser among the GHRP series, exceeding what GHRH analogs produce in a single-exposure setting. The trade-off is rapid desensitisation under continued exposure, attributed to GHSR-1a receptor downregulation. Sermorelin shows neither the same acute spike nor the same drop-off, which makes it the more stable choice for longer-running models.

GHRP-2 is a synthetic pentapeptide agonist at GHSR-1a, the ghrelin receptor, while Sermorelin acts at the GHRH receptor on the same pituitary cells. Because they bind separate receptors, the literature frequently examines a GHRH analog and a GHRP together and reports a larger combined response than either alone. GHRP-2 is also associated with modest reported rises in cortisol and prolactin, which Sermorelin is not.

Sermorelin is a secretagogue that prompts the pituitary to release growth hormone. IGF-1 LR3 is an 83-amino-acid analog of insulin-like growth factor 1 that acts directly at the IGF-1 receptor, downstream of the pituitary, with reduced IGF binding protein affinity and a substantially longer circulating time than native IGF-1. It also exerts negative feedback on endogenous GH output, so the two sit at opposite ends of the same axis.

Recombinant hGH is the complete 191-amino-acid protein acting directly at the GH receptor, producing non-pulsatile supraphysiologic exposure and suppressing endogenous GHRH signalling. Sermorelin works upstream, so output remains limited by somatostatin feedback and pituitary reserve. Research forums often frame this as a potency ranking, but the meaningful difference is whether the study preserves or bypasses axis regulation.

No. These are research-use-only compounds, so Real Peptides does not provide dosing, preparation or administration guidance of any kind. What we do publish is the information a laboratory needs to run its own calculations: net peptide content, purity percentage, mass spectrometry identity confirmation and CAS number, all stated on the certificate of analysis for each batch.

Pricing varies by compound, vial size and purity specification, so current figures are listed on each individual product page rather than quoted as a general range. The more useful cost question for a lab is what verification is included, since a cheaper vial without a published certificate of analysis creates data risk that outweighs the saving.

Real Peptides supplies research-use-only compounds to qualified researchers, laboratories and institutions. None of these compounds are drug products, and none are sold for human or veterinary consumption. Buyers are responsible for ensuring their intended laboratory use complies with applicable institutional and regulatory requirements.

Check four things: purity percentage by HPLC, identity confirmation by mass spectrometry, the CAS number matching the intended compound, and net peptide content as distinct from gross vial weight. The last one matters most in salt-form peptides like sermorelin acetate, because two vials with identical labelled weights can contain different quantities of actual peptide and quietly invalidate a concentration comparison.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA